Literature DB >> 17088437

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Ogechi N Ikediobi1, Helen Davies, Graham Bignell, Sarah Edkins, Claire Stevens, Sarah O'Meara, Thomas Santarius, Tim Avis, Syd Barthorpe, Lisa Brackenbury, Gemma Buck, Adam Butler, Jody Clements, Jennifer Cole, Ed Dicks, Simon Forbes, Kristian Gray, Kelly Halliday, Rachel Harrison, Katy Hills, Jonathan Hinton, Chris Hunter, Andy Jenkinson, David Jones, Vivienne Kosmidou, Richard Lugg, Andrew Menzies, Tatiana Mironenko, Adrian Parker, Janet Perry, Keiran Raine, David Richardson, Rebecca Shepherd, Alex Small, Raffaella Smith, Helen Solomon, Philip Stephens, Jon Teague, Calli Tofts, Jennifer Varian, Tony Webb, Sofie West, Sara Widaa, Andy Yates, William Reinhold, John N Weinstein, Michael R Stratton, P Andrew Futreal, Richard Wooster.   

Abstract

The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. The NCI-60 has been characterized pharmacologically and at the molecular level more extensively than any other set of cell lines. However, no systematic mutation analysis of genes causally implicated in oncogenesis has been reported. This study reports the sequence analysis of 24 known cancer genes in the NCI-60 and an assessment of 4 of the 24 genes for homozygous deletions. One hundred thirty-seven oncogenic mutations were identified in 14 (APC, BRAF, CDKN2, CTNNB1, HRAS, KRAS, NRAS, SMAD4, PIK3CA, PTEN, RB1, STK11, TP53, and VHL) of the 24 genes. All lines have at least one mutation among the cancer genes examined, with most lines (73%) having more than one. Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCI-60 cell lines for molecularly targeted screens.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17088437      PMCID： PMC2705832          DOI： 10.1158/1535-7163.MCT-06-0433

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


  34 in total

1.  Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.

Authors:  David B Whyte; Susan L Holbeck
Journal:  Biochem Biophys Res Commun       Date:  2005-12-15       Impact factor: 3.575

Review 2.  Phosphoinositide 3-kinases as drug targets in cancer.

Authors:  Len Stephens; Roger Williams; Phillip Hawkins
Journal:  Curr Opin Pharmacol       Date:  2005-08       Impact factor: 5.547

3.  Somatic mutations of the protein kinase gene family in human lung cancer.

Authors:  Helen Davies; Chris Hunter; Raffaella Smith; Philip Stephens; Chris Greenman; Graham Bignell; Jon Teague; Adam Butler; Sarah Edkins; Claire Stevens; Adrian Parker; Sarah O'Meara; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Jody Clements; Jennifer Cole; Ed Dicks; Ken Edwards; Simon Forbes; Matthew Gorton; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; David Jones; Vivienne Kosmidou; Ross Laman; Richard Lugg; Andrew Menzies; Janet Perry; Robert Petty; Keiran Raine; Rebecca Shepherd; Alexandra Small; Helen Solomon; Yvonne Stephens; Calli Tofts; Jennifer Varian; Anthony Webb; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Anthony Green; Maggie Knowles; Suet Y Leung; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin T Teh; Siu T Yuen; Sunil R Lakhani; Douglas F Easton; Barbara L Weber; Peter Goldstraw; Andrew G Nicholson; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 4.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Authors:  Pasi A Jänne; Jeffrey A Engelman; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

5.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

6.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.

Authors:  D Wolf; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

7.  Karyotypic complexity of the NCI-60 drug-screening panel.

Authors:  Anna V Roschke; Giovanni Tonon; Kristen S Gehlhaus; Nicolas McTyre; Kimberly J Bussey; Samir Lababidi; Dominic A Scudiero; John N Weinstein; Ilan R Kirsch
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

8.  Neural computing in cancer drug development: predicting mechanism of action.

Authors:  J N Weinstein; K W Kohn; M R Grever; V N Viswanadhan; L V Rubinstein; A P Monks; D A Scudiero; L Welch; A D Koutsoukos; A J Chiausa
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 10.  Targeted cancer therapy.

Authors:  Charles Sawyers
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962
View more
  207 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

3.  STE20-related kinase adaptor protein α (STRADα) regulates cell polarity and invasion through PAK1 signaling in LKB1-null cells.

Authors:  Carrie M Eggers; Erik R Kline; Diansheng Zhong; Wei Zhou; Adam I Marcus
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

4.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

5.  mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.

Authors:  Hongfang Liu; Petula D'Andrade; Stephanie Fulmer-Smentek; Philip Lorenzi; Kurt W Kohn; John N Weinstein; Yves Pommier; William C Reinhold
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

6.  p53 modulates acquired resistance to EGFR inhibitors and radiation.

Authors:  Shyhmin Huang; Sergio Benavente; Eric A Armstrong; Chunrong Li; Deric L Wheeler; Paul M Harari
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

7.  Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.

Authors:  Junqiang Tian; Hongjuan Zhao; Rosalie Nolley; Stephen W Reese; Sarah R Young; Xuejun Li; Donna M Peehl; Susan J Knox
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

8.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

9.  Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.

Authors:  Marie Cumberbatch; Ximing Tang; Garry Beran; Sonia Eckersley; Xin Wang; Rebecca P A Ellston; Simon Dearden; Sabina Cosulich; Paul D Smith; Carmen Behrens; Edward S Kim; Xinying Su; Shuqiong Fan; Neil Gray; David P Blowers; Ignacio I Wistuba; Chris Womack
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

10.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Authors:  Tiffany J Parmenter; Margarete Kleinschmidt; Kathryn M Kinross; Simon T Bond; Jason Li; Mohan R Kaadige; Aparna Rao; Karen E Sheppard; Willy Hugo; Gulietta M Pupo; Richard B Pearson; Sean L McGee; Georgina V Long; Richard A Scolyer; Helen Rizos; Roger S Lo; Carleen Cullinane; Donald E Ayer; Antoni Ribas; Ricky W Johnstone; Rodney J Hicks; Grant A McArthur
Journal:  Cancer Discov       Date:  2014-01-27       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.